Iga Swiatek gets emotional as she addresses 'anxiety' over doping saga

has admitted she still feels "anxiety" about anti-doping controls after serving a one-month suspension. The five-time Grand Slam champion tested positive for the prohibited substance trimetazidine last year, successfully arguing that she was contaminated via melatonin medication.

Swiatek wasn't the only player to face a high-profile doping case last year. Jannik Sinner twice tested positive for a banned substance and also successfully argued that he was contaminated. The World Anti-Doping Agency appealed the "no fault or negligence" finding, and Sinner accepted a three-month suspension in a case-resolution agreement.

Other players have now admitted to fears over the anti-doping system and contamination. Andrey Rublev when it came to keeping up with the controls.

Meanwhile, world No. 1 Aryna Sabalenka admitted she went to .

Swiatek has now had her say after feeling the force of the system last year, admitting she still had anxiety when it came to keeping up with her whereabouts and taking precautions.

"Yeah, honestly, after a couple of years you think about this all the time," the world No. 2 said.

"It gives a little anxiety, I would say, and I'm not only talking about me, because I kind of got used to the system and I've been through the worst, and I was able to come back from that and I was able to solve it, so I feel like nothing can kind of stop me.

"But for sure, I know from even other players that it's not easy, and the whole system is kind of, it's just tough because I didn't have much control over what happened to me, and I can imagine some players, like they're always scared that it can happen to them."

Contamination isn't the only issue on players' minds. They must also keep up with their whereabouts, logging their location in a one-hour timeslot every day for random, out-of-competition testing.

If players have three whereabouts failures in a year, they face a ban of up to two years.

"Yeah, with always giving your location and everything, sometimes, system-wise, it's just hard to catch up," Swiatek explained.

"Because every day when we're travelling, we need to literally say where we are. If we forget we might get a no show and then three no shows and it's ban. So, yeah, there's a lot of pressures with that, and it's not easy to manage that, but it is what it is."

Swiatek has already dealt with her own anti-doping rule violation. Last August, she tested positive for trimetazidine in an out-of-competition sample. On September 12, she was notified of the failed test and immediately provisionally suspended.

The world No. 2 missed three tournaments as a result, but she successfully appealed the provisional suspension after locating the source of contamination for her positive test, and was eligible to return from October 4.

Swiatek and her team identified that a regulated non-prescription melatonin medicine, manufactured and regulated in Poland, was contaminated with trimetazidine and was the source of their positive test.

In November, the International Tennis Integrity Agency said they accepted the positive test was the result of contamination and ruled that Swiatek bore "no significant fault or negligence". She accepted a one-month ban. The 22 days served during the provisional suspension counted towards this so Swiatek was suspended for a further eight days.